Although deficiency in GSTM1 increases susceptibility to kidney disease progression due to enhanced oxidative stress, it may also increase the bioavailability of key antioxidants such as sulforaphane with therapeutic potential in kidney disease
Sprenger HG, Mittenbuehler MJ, Sun Y, Van Vranken JG, Schindler S, Jayaraj A, Khetarpal SA, Vargas-Castillo A, Puszynska AM, Spinelli JB, Armani A
Could a medication replace therapy and other treatment
ALCAR, an acetylated version of l-carnitine, has considerably higher oral bioavailability, due likely to only partial hydrolytic metabolism